Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ranedis Pharmaceuticals
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ranedis Pharmaceuticals is an early-stage biotech company focused on developing therapies for rare and neglected diseases, particularly lysosomal storage disorders and central nervous system disorders. The company leverages an HDAC inhibitor technology licensed from the University of Notre Dame. Its lead program, RND-001, a small molecule targeting histone deacetylase for lysosomal storage and CNS diseases, is in collaboration with AMO Pharma.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
AMO Pharma (collaboration agreement for RND-001 development; AMO Pharma has exclusive option to acquire worldwide rights)
Beyond the preview
Go deeper on Ranedis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ranedis Pharmaceuticals.